RLAY: Relay Therapeutics, Inc.
About
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Current Value
$4.701 Year Return
Current Value
$4.701 Year Return
Key Details
Market Cap
$803.44M
P/E Ratio
-1.84
1Y Stock Return
-39.70%
1Y Revenue Growth
-61.21%
Dividend Yield
0.00%
Price to Book
1.0
Strategies that include RLAY
Stock's related to RLAY
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| XNCR | 56.75% | $1.65B | +27.73% | 0.00% |
| NEU | 45.30% | $5.13B | +3.54% | 1.82% |
| TVTX | 44.66% | $1.51B | +207.79% | 0.00% |
| PGEN | 41.80% | $228.91M | -28.00% | 0.00% |
| DMRC | 41.27% | $694.39M | -2.06% | 0.00% |
| RCKT | 39.18% | $1.20B | -39.83% | 0.00% |
| ALEC | 39.16% | $377.04M | -19.46% | 0.00% |
| OCFC | 38.72% | $1.18B | +47.18% | 4.00% |
| BY | 38.60% | $1.36B | +51.33% | 1.18% |
| HTBK | 37.81% | $645.52M | +24.17% | 4.92% |
| OLP | 37.57% | $617.02M | +46.60% | 6.26% |
| WASH | 37.27% | $628.84M | +39.42% | 5.76% |
| NTB | 36.66% | - | - | 4.69% |
| NVEE | 36.46% | $1.45B | -9.73% | 0.00% |
| CLFD | 36.36% | $398.66M | +4.48% | 0.00% |
| PFC | 36.19% | $990.65M | +38.69% | 4.50% |
| ONIT | 36.03% | $240.15M | +14.44% | 0.00% |
| PRTA | 36.02% | $756.01M | -56.52% | 0.00% |
| PEBO | 36.00% | $1.24B | +18.69% | 4.53% |
| EEX | 35.79% | $964.17M | -8.83% | 0.63% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OKLO | -0.07% | $2.66B | +111.04% | 0.00% |
| AVAL | 0.15% | $791.37M | -4.11% | 7.14% |
| DMLP | -0.23% | $1.58B | +18.00% | 10.54% |
| NTZ | 0.25% | $47.64M | -30.94% | 0.00% |
| HUM | -0.26% | $33.45B | -45.22% | 1.25% |
| VREX | -0.27% | $595.50M | -25.14% | 0.00% |
| MSB | -0.28% | $337.71M | +30.73% | 5.15% |
| MRK | 0.28% | $244.21B | -5.55% | 3.18% |
| EDU | -0.32% | $9.06B | -22.20% | 0.00% |
| JNPR | 0.35% | $11.61B | +30.55% | 2.49% |
| FATBB | -0.40% | $81.94M | -12.91% | 11.69% |
| GTE | -0.45% | $225.69M | -1.28% | 0.00% |
| CHKP | 0.50% | $19.20B | +20.74% | 0.00% |
| HLF | 0.51% | $778.11M | -38.09% | 0.00% |
| MOH | -0.52% | $16.16B | -21.56% | 0.00% |
| ALAR | -0.56% | $89.09M | +158.08% | 0.00% |
| EZPW | 0.58% | $655.76M | +45.24% | 0.00% |
| KRRO | 0.60% | $436.84M | +20.68% | 0.00% |
| VIRT | -0.63% | $3.17B | +110.38% | 2.60% |
| LUNA | 0.66% | $55.69M | -71.48% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MSDL | -9.58% | $1.83B | +0.66% | 7.26% |
| STG | -9.11% | $35.67M | +7.92% | 0.00% |
| CME | -8.71% | $82.76B | +9.21% | 1.98% |
| LFVN | -8.70% | $169.84M | +130.61% | 1.10% |
| MCK | -8.37% | $78.15B | +35.51% | 0.42% |
| LITB | -8.11% | $35.48M | -75.45% | 0.00% |
| LUMO | -7.76% | $37.45M | +41.97% | 0.00% |
| KGS | -7.56% | $3.37B | +110.22% | 4.11% |
| CBOE | -6.63% | $21.46B | +15.84% | 1.11% |
| ZCMD | -6.51% | $2.80M | -88.67% | 0.00% |
| NNVC | -6.49% | $19.66M | +25.69% | 0.00% |
| HUSA | -6.27% | $16.69M | -11.56% | 0.00% |
| CLMT | -6.00% | $1.79B | +35.14% | 0.00% |
| TCTM | -5.76% | $8.10M | -42.99% | 0.00% |
| PULM | -5.67% | $19.83M | +202.98% | 0.00% |
| PGR | -4.74% | $149.10B | +57.29% | 0.45% |
| MNOV | -4.65% | $93.19M | +2.15% | 0.00% |
| COR | -4.57% | $47.48B | +21.20% | 0.86% |
| ACI | -4.53% | $11.16B | -9.32% | 2.50% |
| CNSL | -4.44% | $548.51M | +9.98% | 0.00% |
ETF's related to RLAY
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 47.82% | $6.58B | 0.35% |
| PBE | 47.81% | $258.53M | 0.58% |
| IBB | 47.67% | $6.66B | 0.45% |
| GNOM | 46.07% | $70.59M | 0.5% |
| IWC | 44.37% | $933.99M | 0.6% |
| ARKG | 43.73% | $1.13B | 0.75% |
| ISCG | 43.69% | $640.00M | 0.06% |
| IAT | 43.52% | $725.82M | 0.4% |
| IWO | 43.47% | $12.56B | 0.24% |
| MDYV | 43.34% | $3.25B | 0.15% |
| VBR | 43.22% | $32.03B | 0.07% |
| VTWO | 43.08% | $12.38B | 0.1% |
| IWM | 43.05% | $75.73B | 0.19% |
| FBT | 42.89% | $1.11B | 0.56% |
| SPYV | 42.73% | $24.94B | 0.04% |
| KOMP | 42.72% | $2.09B | 0.2% |
| ARKK | 42.69% | $6.28B | 0.75% |
| IUSV | 42.68% | $19.83B | 0.04% |
| SIZE | 42.67% | $329.63M | 0.15% |
| SMOT | 42.66% | $374.04M | 0.49% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| KCCA | -0.34% | $220.51M | 0.87% |
| SHV | -0.74% | $18.13B | 0.15% |
| DBMF | 0.81% | $1.02B | 0.85% |
| MINT | 0.81% | $11.62B | 0.35% |
| CORN | -0.92% | $61.12M | 0.2% |
| PDBC | -1.02% | $4.40B | 0.59% |
| DBC | -1.26% | $1.39B | 0.87% |
| XHLF | -1.29% | $874.27M | 0.03% |
| GSG | -1.40% | $914.42M | 0.75% |
| SGOV | -1.41% | $27.53B | 0.09% |
| FBY | 1.61% | $127.69M | 0.99% |
| BILZ | 1.64% | $563.02M | 0.14% |
| TPMN | -1.89% | $40.60M | 0.65% |
| HDRO | -1.91% | $164.26M | 0.3% |
| HIGH | 1.99% | $302.78M | 0.51% |
| IVOL | 2.23% | $548.70M | 1.02% |
| TBIL | 2.42% | $4.38B | 0.15% |
| COMT | -2.52% | $829.06M | 0.48% |
| DBA | 2.75% | $755.88M | 0.93% |
| BOXX | 2.93% | $4.43B | 0.1949% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -27.62% | $388.04M | 1.43% |
| VIXY | -27.45% | $195.31M | 0.85% |
| TAIL | -15.78% | $67.98M | 0.59% |
| CTA | -12.76% | $350.27M | 0.78% |
| USDU | -12.54% | $201.97M | 0.5% |
| UUP | -12.44% | $309.25M | 0.77% |
| EQLS | -10.12% | $76.08M | 1% |
| BSCO | -9.23% | $2.35B | 0.1% |
| AGZD | -9.08% | $142.76M | 0.23% |
| KMLM | -9.04% | $353.87M | 0.9% |
| DBE | -8.75% | $50.13M | 0.77% |
| JBBB | -8.62% | $1.26B | 0.49% |
| WEAT | -8.60% | $120.27M | 0.28% |
| CANE | -8.58% | $17.72M | 0.29% |
| IBHD | -7.45% | $327.80M | 0.35% |
| XBIL | -5.92% | $637.70M | 0.15% |
| IBDP | -4.29% | $2.11B | 0.1% |
| UNG | -3.91% | $908.80M | 1.06% |
| DBO | -3.43% | $217.57M | 0.77% |
| COMT | -2.52% | $829.06M | 0.48% |
News
SeekingAlpha
Absci Corporation has secured key partnerships but lacks advanced assets. Find out why ABSI stock is still a speculative investment despite its AI potential.
Yahoo
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Yahoo
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in the following upcoming fireside chats: Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ETStifel 2024 Healthcare Conference on Monday, November 18, 2024 at 10:
Yahoo
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments at end of Q3 2024, expected to fund operations into second half of 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine c
Yahoo
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company t
Yahoo
Key Insights Institutions' substantial holdings in Relay Therapeutics implies that they have significant influence over...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.